T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints

Trends Immunol. 2017 Feb;38(2):104-115. doi: 10.1016/j.it.2016.11.005. Epub 2016 Dec 7.

Abstract

Glioblastoma is an aggressive and incurable primary brain tumor. While the blockade of immune checkpoints leads to reversal of T cell exhaustion in many cancers, the efficacy of this therapy in glioblastoma requires further consideration of the brain microenvironment beyond T cell activity. Neural cells are crucially dependent on glucose for survival, and tumor cells rabidly consume glucose; the glucose-deprived microenvironment further elevates immune checkpoint molecules to benefit tumor growth and exacerbate T cell exhaustion. We review here how immune checkpoints drive exhaustion in T cells while favoring tumor metabolism, and discuss how glucose competition in the unique CNS milieu is an important consideration to improve the outcomes of immune checkpoint blockade in glioblastoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / immunology*
  • Brain Neoplasms / therapy
  • Cellular Senescence
  • Costimulatory and Inhibitory T-Cell Receptors / antagonists & inhibitors*
  • Costimulatory and Inhibitory T-Cell Receptors / immunology
  • Glioblastoma / immunology*
  • Glioblastoma / therapy
  • Glucose / metabolism
  • Humans
  • Immune Tolerance
  • Immunotherapy / methods*
  • T-Lymphocytes / immunology*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Costimulatory and Inhibitory T-Cell Receptors
  • Glucose

Grants and funding